Criteria for inclusion: a) Program has completed phase-2b or later and is non-partnered; AND b) Company lacks the financial resources to commercialize the product on its own.
Edits: Added ONCY who have now started a Phase 3 in refractory SCC Head & Neck Cancer with a FDA SPA in hand. ONCY is also more than midway through a closely watched Phase 2 trial for first line kras+ NSCLC lung cancer. Preliminary data in this Phase 2 trial is due in Q3-2010. ONCY may partner or raise funds after this data is released as the company is currently only funded to complete and analyze the first-look portion of the Phase 3 at this time.
Company Product Phase Indication (notes) ======= ======= ===== ================== ARNA Lorcaserin NDA Obesity ARYX Budiodarone 2B Atrial Fibrillation ARYX Tecarfarin 3 VTE prevention (failed initial ph-3) BPAX Libigel 3 Female Sexual Desire Disorder DYAX Kalbitor US app acute HAE (seeking ex-US partner) HNAB Marqibo 2B ALL (ENZN failed acc. approval in NHL) JAV Dyloject NDA Post-op pain (approved in UK) JAV Ketamine 3 Acute pain ONCY Reolysin 3 SCC Head & Neck cancer (ph-3 SPA) OREX Contrave NDA Obesity OXGN Zybrestat 3 Anaplastic thyroid cancer MNKD Afrezza BLA Diabetes (CRL rec’d 3/15/10) Pharming Rhucin BLA HAE (CHMP decision expctd Jun 2010) SOMX Silenor apprvd Insomnia (low dose of generic doxepin) SVNT Krystexxa BLA Gout (response to CRL submtd 3/30/10) VVUS Qnexa NDA Obesity
Procedure for Updating Table
1. Copy the text in this post into a word processor.
2. Using a monospace font (e.g. Courier) to facilitate tabular alignment, make your additions and modifications, inserting them in the table in alphabetical order. NOTE: use spaces rather than tab characters.
3. Add a brief note in the “Edits:” line atop the table to describe your changes.
4. Insert the iHub formatting directives: Put [ pre ] at the beginning of the table without the surrounding spaces, and put [ /pre ] at the end of the table without the surrounding spaces.